Kairos Pharma, Ltd. (KAPA) vs Silo Pharma, Inc. (SILO)

Kairos Pharma, Ltd. and Silo Pharma, Inc. are both Biotechnology companies. Kairos Pharma, Ltd. is the larger, with a market value of $2.3M against $1.9M — 1.2× the size. Across the 10 metrics below, Silo Pharma, Inc. leads on 6 and Kairos Pharma, Ltd. on 4.

Valuation

Metric KAPA SILO Biotechnology median
P/E n/m n/m 8.50
P/S n/m 18.00 9.71
P/B 0.44 0.27 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.14 0.90 0.64
EV/Sales n/m (54.56) 9.21
Earnings yield (326.58%) (369.34%) (33.15%)
Free cash flow yield (216.16%) (302.55%) (25.50%)

Profitability

Metric KAPA SILO Biotechnology median
Gross margin — 11.81% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (113.96%) (91.23%) (56.36%)
Return on assets (104.32%) (70.96%) (48.04%)
Return on invested capital (322.91%) 0.00% 0.00%

Growth

Metric KAPA SILO Biotechnology median
Revenue growth (TTM) — 0.00% 6.02%
EPS growth (last fiscal year) (30.44%) 57.98% 30.26%
Revenue growth, 5-year CAGR — 12.17% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KAPA SILO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.98 5.36 4.72
Net debt to EBITDA 1.65 1.61 0.96

Dividend

Metric KAPA SILO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KAPA SILO Biotechnology median
Market cap 2.27m 1.91m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack